219 related articles for article (PubMed ID: 17575540)
21. Differential methylation of cell-free circulating DNA among patients with pancreatic cancer versus chronic pancreatitis.
Liggett T; Melnikov A; Yi QL; Replogle C; Brand R; Kaul K; Talamonti M; Abrams RA; Levenson V
Cancer; 2010 Apr; 116(7):1674-80. PubMed ID: 20143430
[TBL] [Abstract][Full Text] [Related]
22. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head.
Liao Q; Zhao YP; Yang YC; Li LJ; Long X; Han SM
Hepatobiliary Pancreat Dis Int; 2007 Dec; 6(6):641-5. PubMed ID: 18086633
[TBL] [Abstract][Full Text] [Related]
23. [Diagnostic value of serum Ca 19-9 antigen in chronic pancreatitis and pancreatic adenocarcinoma].
Nouts A; Lévy P; Voitot H; Bernades P
Gastroenterol Clin Biol; 1998 Feb; 22(2):152-9. PubMed ID: 9762189
[TBL] [Abstract][Full Text] [Related]
24. Serum prostate-specific antigen in pancreatic disease.
Pezzilli R; Bertaccini A; Billi P; Zanarini L; Miglio F; Martorana G
Ital J Gastroenterol Hepatol; 1999 Oct; 31(7):580-3. PubMed ID: 10604096
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic usefulness of serum interleukin 6 (IL-6) and C-reactive protein (CRP) in the differentiation between pancreatic cancer and chronic pancreatitis.
Mroczko B; Groblewska M; Gryko M; Kedra B; Szmitkowski M
J Clin Lab Anal; 2010; 24(4):256-61. PubMed ID: 20626020
[TBL] [Abstract][Full Text] [Related]
26. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
[TBL] [Abstract][Full Text] [Related]
27. Value of serum IgG4 in the diagnosis of autoimmune pancreatitis and in distinguishing it from pancreatic cancer.
Ghazale A; Chari ST; Smyrk TC; Levy MJ; Topazian MD; Takahashi N; Clain JE; Pearson RK; Pelaez-Luna M; Petersen BT; Vege SS; Farnell MB
Am J Gastroenterol; 2007 Aug; 102(8):1646-53. PubMed ID: 17555461
[TBL] [Abstract][Full Text] [Related]
28. Increased levels of both carbohydrate antigen 19-9 and duke pancreatic monoclonal antigen type 2 reflect postoperative prognosis in patients with pancreatic carcinoma.
Shibata K; Iwaki K; Kai S; Ohta M; Kitano S
Pancreas; 2009 Aug; 38(6):619-24. PubMed ID: 19436235
[TBL] [Abstract][Full Text] [Related]
29. The role of quantitative NPTX2 hypermethylation as a novel serum diagnostic marker in pancreatic cancer.
Park JK; Ryu JK; Yoon WJ; Lee SH; Lee GY; Jeong KS; Kim YT; Yoon YB
Pancreas; 2012 Jan; 41(1):95-101. PubMed ID: 21778928
[TBL] [Abstract][Full Text] [Related]
30. Neutrophil Gelatinase-Associated Lipocalin (NGAL) concentration in urine is superior to CA19-9 and Ca 125 in differentiation of pancreatic mass: Preliminary report.
Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
Cancer Biomark; 2016 Mar; 16(4):537-43. PubMed ID: 27002756
[TBL] [Abstract][Full Text] [Related]
31. Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis.
Su SB; Qin SY; Chen W; Luo W; Jiang HX
World J Gastroenterol; 2015 Apr; 21(14):4323-33. PubMed ID: 25892884
[TBL] [Abstract][Full Text] [Related]
32. The assessment of serum and diagnostic peritoneal lavage concentration of matrix metalloproteinase-2, matrix metalloproteinase-9, carbohydrate antigen 19-9, and carcinoembryonic antigen in patients with pancreatic cancer and chronic pancreatitis.
Dranka-Bojarowska D; Lewinski A; Lekstan A; Gajda M; Ciosek J; Mrowiec S
J Physiol Pharmacol; 2020 Oct; 71(5):. PubMed ID: 33571962
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of matrix metalloproteinase 7 in plasma and pancreatic juice as a biomarker for pancreatic cancer.
Kuhlmann KF; van Till JW; Boermeester MA; de Reuver PR; Tzvetanova ID; Offerhaus GJ; Ten Kate FJ; Busch OR; van Gulik TM; Gouma DJ; Crawford HC
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):886-91. PubMed ID: 17507610
[TBL] [Abstract][Full Text] [Related]
34. Neopterin--a potential factor for differentiation between pancreatic cancer and chronic pancreatitis.
Piecuch J; Rudzki M; Orkisz W; Swietochowska E; Wielkoszyński T; Waniczek D; Arendt J; Sosada K; Zurawiński W; Ładny JR
Hepatogastroenterology; 2008; 55(81):258-61. PubMed ID: 18507120
[TBL] [Abstract][Full Text] [Related]
35. The presence of the proteolysis-inducing factor in urine does not predict the malignancy of a pancreatic tumour.
Teich N; Kleeff J; Lochs H; Mössner J; Keim V; Friess H; Ockenga J
BMC Gastroenterol; 2005 Jun; 5():20. PubMed ID: 15969757
[TBL] [Abstract][Full Text] [Related]
36. Elevated tumor marker CA 19-9 in the differential diagnosis of pancreatic mass lesions.
Cwik G; Wallner G; Skoczylas T; Krzyzanowski M; Ciechainski A; Madro P
Ann Univ Mariae Curie Sklodowska Med; 2004; 59(2):213-8. PubMed ID: 16146081
[TBL] [Abstract][Full Text] [Related]
37. [Resistin-- a new laboratory marker useful in diagnosis of acute pancreatitis?].
Leśniowski B; Kumor A; Jasińska A; Daniel P; Pietruczuk M; Małecka-Panas E
Pol Merkur Lekarski; 2007 May; 22(131):385-7. PubMed ID: 17679375
[TBL] [Abstract][Full Text] [Related]
38. Elevated levels of plasma fibrinogen in patients with pancreatic cancer: possible role of a distant metastasis predictor.
Guo Q; Zhang B; Dong X; Xie Q; Guo E; Huang H; Wu Y
Pancreas; 2009 Apr; 38(3):e75-9. PubMed ID: 19276866
[TBL] [Abstract][Full Text] [Related]
39. Evaluating the role of serum elastase 1 in the diagnosis of pancreatic cancer.
Wu D; Qian JM; Deng RX; Jiang WJ; Chen YJ; Liu XH; Lu XH
Chin J Dig Dis; 2006; 7(2):117-20. PubMed ID: 16643340
[TBL] [Abstract][Full Text] [Related]
40. CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease.
Morris-Stiff G; Teli M; Jardine N; Puntis MC
Hepatobiliary Pancreat Dis Int; 2009 Dec; 8(6):620-6. PubMed ID: 20007080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
